Table-2.

ERK inhibitor PD98059 partially abolishes Intralipid-induced cardioprotection against ischemia/ reperfusion injury

	LVSP mmHg	LVEDP mmHg	LVDP mmHg	HR Beats/min
Baseline
CTRL	99±10	4±2	95±11	188±44
ILP	96±6	2±1	94±6	161±32
PD+ILP	80±6	2±1	78±6	193±25
PD	92±10	2±1	90±10	179±36
Reperfusion
10 min
CTRL	15±2	4±1	11±3	135±28
ILP	80±16**	3±1	77±5**	139±32
PD+ILP	35±6##	3±1	32±6##	184±43
PD	32±9	15±6	17±3	150±18
20 min
CTRL	16±3	4±2	12±3	209±28
ILP	77±12**	8±3	69±6**	169±25
PD+ILP	41±7##	3±2	38±5##	222±35
PD	19±3	4±2	15±2	166±18
30 min
CTRL	16±2	5±1	11±2	223±39
ILP	73±13**	6±2	67±7**	177±18
PD+ILP	42±8##	2±1	40±7##	249±47
PD	23±4	5±3	18±1	169±31
40 min
CTRL	19±4	6±2	13±3	219±36
ILP	80±16**	5±2	75±8**	157±14
PD+ILP	47±7##	2±1	45±6##	221±29
PD	23±1	4±2	19±2	165±27

Cardiac functional recovery parameters of left ventricular systolic pressure (LVSP); left ventricular end-diastolic pressure (LVEDP); left ventricular developed pressure (LVDP) and heart rate (HR) before ischemia (baseline) and at different times of reperfusion in control group (CTRL), 1% Intralipid (ILP), 1% Intralipid+PD98059 (ILP+PD) and PD98059 alone (PD).

Values are Mean ± SEM;

^**P < 0.01 vs. CTRL and

^##P < 0.01 vs. ILP (n = 6).